Open AccessTreatment and secondary prevention of venous thromboembolism in cancer patients
Author(s) -
G. A. Shakaryants,
Д. А. Буданова,
Kirill Lobastov,
Н. В. Хабарова,
Yu Yu Kirichenko,
Yu. N. Belenkov
Publication year - 2020
Publication title -
kardiologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.159
H-Index - 16
eISSN - 2412-5660
pISSN - 0022-9040
DOI - 10.18087/cardio.2020.3.n904
Subject(s) - medicine , venous thromboembolism , intensive care medicine , anticoagulant therapy , anticoagulant , cancer , surgery , thrombosis
Oncological patients are a high-risk group for venous thromboembolic complications. These complications significantly impair the outcome of antitumor treatment and take a leading place in the structure of mortality. Treatment of venous thromboembolic complications in oncological patients is a serious challenge. When selecting an anticoagulant, the physician should consider its efficacy and safety and possible drug interactions. Based on results of multiple studies presented in this article, physicians will be able to choose an optimum therapeutic tactics and secondary prevention of thromboembolic complications for this group of patients.